Pharma ADMET Testing: World Industry and Market Prospects 2015-2025

LONDON, October 12, 2015 /PRNewswire/ --

ADMET Products and Services - Your Guide to Trends and Revenue Potentials
The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by visiongain.

Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing.

Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions for those pharma R&D technologies. There is much opportunity in that fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments. Commercial drivers and restraints for each submarket are also provided, as are revenue forecasts to 2025.
• In vitro ADMET testing
• In vivo ADMET applications
• In silico ADMET uses.

Our new study predicts the pharma ADMET testing market will expand throughout the forecast period, 2015 to 2025, driven by increased demand for that screening and advances in technology enhancing the reliability and predictive capabilities of those assays.

Leading companies and potential for market growth
Overall revenue for the pharma ADMET testing market will reach $10.51bn in 2019, our work forecasts. We predict strong revenue growth through to 2025, as drug developers select stronger product candidates for development, using ADMET technology.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Our work also analyses prominent companies in that market. See visiongain's analysis of leading companies, including these:
• Agilent Technologies
• BIOVIA
• Cyprotex
• Bio-Rad Laboratories
• Quintiles
• CMIC
• Charles River Laboratories
• WuXi PharmaTech
• Promega Corporation
• Sigma-Aldrich.

A company profile gives you the following information where available:
• Recent historical revenues
• Discussion of a company's activities, technologies and outlook
• Brief assessment of the company's ADMET strategy.

With that information you will assess competitors' capabilities, progress, and commercial prospects, helping you stay ahead and benefit your reputation for insight.

National markets for those drug development technologies
Our study shows you prospects for ADMET sales in developed and developing countries. You will see individual revenue forecasts to 2025 for 12 countries:
• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC)
• South Korea.

With our analysis you will investigate regions with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

What forces affect the pharma ADMET testing industry?
Our new report discusses issues and events affecting the pharmaceutical ADMET testing industry  and market. You will find discussions, including qualitative analyses:
• Rising demand for early ADMET testing
• Developments in that drug screening technology.

You will see discussions of technological, commercial, and economic issues, with emphasis on the competitive landscape and business outlooks. Discover what the future holds.

How Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 helps
In particular, our new investigation gives the following knowledge to benefit your work:
• Revenue forecasts to 2025 for the pharma ADMET testing market - discover that industry's commercial prospects, finding what revenues and growth are possible
• Revenue forecasts to 2025 for three submarkets - explore sales potentials of in vitro, in vivo and in silico testing
• Revenue forecasts to 2025 for 12 leading national markets - US, EU5 (Germany, France, UK, Italy and Spain), Japan, Brazil, Russia, India, China and South Korea
• Assessment of leading companies - assess competitors, exploring their product and service portfolios, strategic developments and commercial outlooks
• Exclusive interviews with three companies - gain opinions from MultiCASE Inc., Optivia Biotechnology and Takara Bio Europe AB, seeing what participants say and do
• Discussion of what stimulates and restrains companies and the market - examine forces affecting those technologies and their providers
• Prospects for established firms and those seeking to enter the industry - discover what the future holds, helping you stay ahead in knowledge.

There you will find quantitative and qualitative analyses with independent predictions. That way you will receive information that only our report contains, staying informed on business intelligence.

Data and discussions found nowhere else, helping your research, analyses and decisions
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's new study is for everybody needing analyses of the pharma ADMET testing market and that industry's leading companies. There you will find data, trends and predictions. Stay ahead by getting that report here now.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request an exec summary of this report please email Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1512/Pharma-ADMET-Testing-World-Industry-and-Market-Prospects-2015-2025

Companies Listed

AbD Serotec (now part of Bio-Rad Laboratories)
ACEA Biosciences
Aegis Analytical Corp
Agenzia Italiana del Farmaco
Agência Nacional de Vigilância Sanitária (ANVISA)
Agilent Technologies
Albany Molecular Research
Apredica, LLC
Associação Brasileira de CROs
Association of Clinical Trial Organisations (ACTO) [Russia]
AstraZeneca
Bayer
BD Biosciences
Beckman Coulter
Bio-Rad Laboratories
BIOVIA
Boehringer Ingelheim
Caliper Life Sciences
Cambridge Cell Networks
Catalent Pharma Solutions
Catalina Health (now part of InVentiv Health)
Celerion
Cellartis
Cellectis AB
Cellumen
Celsis International
Charles River Laboratories
ChemSW
Chinese Ministry of Commerce
Clinipace Worldwide
ClinStar (now part of PRA Health Sciences)
CMIC Holdings
Council for Economic Defense [Brazil]
Cromos Pharma
CROMSOURCE
Cyprotex
Department of Health and Human Services [US]
EF Education First
Entelos Holdings
Environmental Protection Agency [US]
EPS Holdings, Inc., formerly EPS Corporation
European Commission
European Medicines Agency (EMA)
Fish and Wildlife Service [US]
Food and Drug Administration (FDA) [US]
Frontage Laboratories
GCP ClinPlus
I3 Research (now part of InVentiv Health)
ICON plc
INC Research
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
InVentiv Health
Harlan Laboratories (now part of Huntingdon Life Sciences)
Helmholtz Association
Helmholtz Zentrum München (German Research Center for Environmental Health)
Hisun Pharmaceuticals
Hospital Italiano of Buenos Aires
Huntingdon Life Sciences
JCL Bioassay Corporation (now part of CMIC)
Kendle (now part of INC Research)
Kforce Clinical Research (now part of InVentiv Health)
Korea Drug Development Fund
Korea Food and Drug Administration (KFDA)
Korea National Enterprise for Clinical Trials
L'Agence Nationale de Sécurité du Médicament (l'ANSM)
Les Entreprises du Medicament (LEEM)
Life Technologies Corporation
LSK
Malaysian Biotechnology Corporation
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
Merck & Co.
Merck KGaA
Mitsubishi Gas Chemical Company, Inc.
MultiCASE
Nagoya University
National Association for Biomedical Research [US]
National Cancer Institute (NCI) [US]
National Center for Advancing Translational Sciences [US]
National Centre for Computational Toxicology [US}
National Enterprise for Clinical Trials [South Korea]
National Human Genome Research Institute [US]
National Institute of Environmental Health Sciences [US]
National Institutes of Health (NIH) [US]
National Toxicology Program [US]
New England Antivivisection Society
New York Stock Exchange
Noray Bioinformatics
Novartis
Novotech
Oncobiologics
Optivia Biotechnology
Organovo Holdings, Inc.
Parexel
PerkinElmer
Pharmaron
PharmaNet Development Group (now part of InVentiv Health)
PRA Health Sciences
Prodia Clinical Laboratory
Promega Corporation
Proteomics
ProTrials Research
Quintiles
ReSearch Pharmaceutical Services (now part of PRA Health Sciences)
Rosa & Co
Russian Ministry of Public Health
Samsung
Sekisui Medical Co.
Seoul National University Hospital Clinical Trials Center
Shanghai Clinical Research Center to
ShangPharma
Sigma-Aldrich
Simulations Plus
Sugi Medical Co. (now part of CMIC)
Taconic Biosciences
Takara Bio Europe AB
Takara Bio Inc
Tecan Group
Thermo Fisher Scientific
Tigermed Consulting
VelQuest
Vialis
Vietnam Ministry of Health Administration of Science, Technology and Training (ASST)
West Coast Clinical Trials
World Health Organization (WHO)
WuXi PharmaTech
Xceleron
XenoBiotic Laboratories
XenoTech (now part of Sekisui)
Yungjin Pharmaceutical
Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

.